Genmab — April 2021
-
Vi må håbe at guidance er lavt sat, og at en opjustering vil vinde noget af det tabte tilbage.
-
Mon der er nogle investorer der lugter gode salgstal i morgen?
-
Roche publicerer nye sklerosedata for at holde Novartis fra døren
Med den nyligt godkendte sklerosemedicin Kesimpta - oprindeligt udviklet af Genmab - er Novartis i fuld gang med at lange ud efter Roches dominerende lægemiddel på markedet, og nu prøver Roche at slå igen.
(medwatch.dk)
-
Langers Skarpe: Deltag i festen, men undgå tømmermænd og forlad den i tide
-
Health Canada-Approved Treatment for Patients with Newly Diagnosed Light Chain (AL) Amyloidosis / Dara https://www.newswire.ca/news-releases/darzalex-r-sc-becomes-the-first-and-only-health-canada-approved-treatment-for-patients-with-newly-diagnosed-light-chain-al-amyloidosis-a-rare-disease-849615211.html
-
CEO Jan van de Winkel rykker op på førstepladsen i Økonomisk Ugebrevs årlige CEO Performance-ranking. https://ugebrev.dk/ledelse/genmab-vinder-ceo-performance-redningsplan-blev-succes/
-
waiting for this, New trial - A Multicenter Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab https://clinicaltrials.gov/ct2/show/NCT04847596
-
These results obtained after 12 months of maintenance therapy reveal the potential of D-VRd and D-R maintenance as a new treatment for patients with NDMM who are eligible for transplant.
https://multiplemyelomahub.com/medical-information/daratumumab-plus-vrd-vs-vrd-in-newly-diagnosed-mm-griffin-trial-updated-analysis -
-
God morgen.
-
Asien: Frygt for nye nedlukninger presser japanske selskaber https://www.proinvestor.com/investornyt/674191/asien-frygt-for-nye-nedlukninger-presser-japanske-selskaber
-
Genmab/DNB: Kursmål løftet 9 pct. https://www.proinvestor.com/investornyt/674193/genmab-dnb-kursmal-loftet-9-pct-gent
-
Tirsdagens danske avisuddrag med Danske Bank, Lego og Hummel https://www.proinvestor.com/investornyt/674194/tirsdagens-danske-avisuddrag-med-danske-bank-lego-og-hummel
-
God morgen
-
Genmab/Deutsche Bank: Indleder med "køb" og kursmål på 2750 kr. https://www.proinvestor.com/investornyt/674199/genmab-deutsche-bank-indleder-med-kob-og-kursmal-pa-2750-kr
(15:12)Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind